MADRIGAL PHARMACEUTICALS INC

Insider tax‑withholding sales at Madrigal show no market impact, just disciplined RSU management by CEO William Sibold.

Insightful look at Madrigal Pharmaceuticals’ insider buying—Taub’s free stock grant, board’s 3.3 M shares, and bullish implications for investors.

Insider sales show Madrigal’s long‑term confidence: CMO’s automatic 844‑share sale reflects vesting, while top execs’ bulk buying signals optimism for the cardiovascular pipeline, despite a steep 52‑week low.

Insightful insider buying: CFO Dier Mardi’s recent RSU purchase shows confidence in Madrigal’s future, despite volatility, giving investors a bullish signal.

CEO Madrigal RSU grant signals confidence in cardiovascular pipeline – insider buying hints a potential rebound toward $615 high.

Explore how Kelley Shannon T’s 4,017 RSU grant at Madrigal Pharm highlights insider confidence, long‑term equity alignment, and potential impact on investor confidence and future earnings.

Insider buys show Carole Huntsman’s confidence in Madrigal’s long‑term biotech prospects.

Insider buy of 2,500 shares in Madrigal Pharmaceuticals signals growing confidence; learn how this modest move hints at future upside despite a negative P/E.

Paul Friedman’s 2026 insider trades: buying Madrigal stock at a steep discount while selling large blocks at high prices – a mixed signal of long‑term conviction and short‑term profit‑taking for investors to consider.